Loading...
Loading...
Supernus Pharmaceuticals,
Inc.
SUPN today announced that on June 26, 2013 the Company received
a Paragraph IV Notice Letter from Watson Laboratories, Inc. ("Watson")
advising Supernus of the filing by Watson of an Abbreviated New Drug
Application seeking approval for oxcarbazepine extended-release tablets.
Supernus is currently reviewing the details of this Notice Letter and intends
to vigorously enforce its intellectual property rights relating to Oxtellar
XR. The product is currently protected by two issued patents that are listed
in the FDA's Orange Book.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on developing and commercializing products for the treatment of central
nervous system, or CNS, diseases. The Company has one marketed product for
epilepsy, Oxtellar XR^TM (extended release oxcarbazepine), and one tentatively
approved product for epilepsy, Trokendi XR^TM (extended release
topiramate). The Company is also developing several product candidates in
psychiatry to address large market opportunities in ADHD, including ADHD
patients with impulsive aggression. These product candidates include SPN-810
for impulsive aggression in ADHD and SPN-812 for ADHD.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in